Search
Enanta Pharmaceuticals Inc
ENTAAdd to Watchlist
12.600USD
-0.400-3.08%
Close 07-31 16:00（ET）Quotes delayed by 15 min
366.39MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Enanta Pharmaceuticals Inc is 8.29, ranking 46 out of 155 in the Pharmaceuticals industry. The average price target is 20.00, with a high of 28.00 and a low of 11.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
22.833
Target Price
+81.22%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Enanta Pharmaceuticals Inc
ENTA
6
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
32
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Enanta Pharmaceuticals Inc's expected revenue for the next quarter?
Enanta Pharmaceuticals Inc's expected revenue is 16.80M.
What is Enanta Pharmaceuticals Inc's price target?
Analysts forecast that Enanta Pharmaceuticals Inc's price target is USD 20.00, with the highest forecast at USD 28.00 and the lowest forecast at USD 11.00.
How have Enanta Pharmaceuticals IncENTA's recent earnings per share performed?
The market expectation was USD -0.45, while Enanta Pharmaceuticals IncENTA's earnings per share (EPS) for the previous quarter was USD -0.42. EPS for the next quarter is expected at USD -0.51.
What is the analyst rating for Enanta Pharmaceuticals Inc?
Based on the ratings of Enanta Pharmaceuticals Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.